Mark Goldsmith, Revolution Medicines Inc. president, CEO and chairman, talks about grappling with RAS mutations.

Download transcript

Howard Fillit, founding executive director and chief science officer at the Alzheimer’s Drug Discovery Foundation, shares his insights on the impact of financial investments driving these therapies.

Download transcript

Biopharma deal-making activity, a closely watched marker of industry health, was alive and well in the second quarter. BioWorld Senior Analyst Karen Carey sifts through the numbers.

Download transcript

Michel Detheux, president and CEO of Iteos Therapeutics Inc., discusses what his company brings GSK in a massive new deal.

Download transcript

Biogen’s vice president of global and U.S. medical affairs for Alzheimer’s disease offers insight into Aduhelm.

Download transcipt